default author photo

Yuan Gao

Guangzhou Medical University - The First Clinical Medical School

SCHOLARLY PAPERS

2

DOWNLOADS

99

TOTAL CITATIONS

1

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

Interplay of Chronic Obstructive Pulmonary Disease and Colorectal Cancer Development: Unravelling the Mediating Role of Fatty Acids Through a Comprehensive Multi-Omics Analysis

Number of pages: 29 Posted: 14 Apr 2023
Youtao Zhou, Zikai Lin, Shuojia Xie, Yuan Gao, Haobin Zhou, Yuewu Fu, Cuiyan Yang and Chuanfeng Ke
Guangzhou Medical University - The First Clinical Medical School, Guangzhou Medical University - State Key Laboratory of Respiratory Disease, Guangzhou Medical University - State Key Laboratory of Respiratory Disease, Guangzhou Medical University - The First Clinical Medical School, Guangzhou Medical University - The First Clinical Medical School, Jinan University - Department of General Surgery, Guangzhou Medical University - Department of Gastrointestinal Surgery and Guangzhou Medical University - Department of Gastrointestinal Surgery
Downloads 66 (907,769)

Abstract:

Loading...

chronic obstructive pulmonary disease, colorectal cancer, fatty acid, multi-omics, mediating factor

2.

Efficacy and Safety of First Line Treatments for Patients with HER2-Negative Advanced Gastric or Gastroesophageal Junction Cancer: Systematic Review and Network Meta-Analysis

Number of pages: 40 Posted: 08 Nov 2023
Zikai Lin, Yuan Gao, Cuiyan Yang, Gongpin Shu, Youtao Zhou, Bailiang Liu, Baojun Liu and Chuanfeng Ke
Guangzhou Medical University - State Key Laboratory of Respiratory Disease, Guangzhou Medical University - The First Clinical Medical School, Guangzhou Medical University - Department of Gastrointestinal Surgery, Guangzhou Medical University, Guangzhou Medical University - The First Clinical Medical School, Guangzhou Medical University, Guangzhou Medical University and Guangzhou Medical University - Department of Gastrointestinal Surgery
Downloads 33 (1,277,121)
Citation 1

Abstract:

Loading...

gastric cancer, first line treatment, immunotherapy, HER2-negative, safety